Since 2015，the State Council，National Development and Reform Commission，the Ministry of Science and Technology，and National Intellectual Property Administration have issued a number of policy documents to support and encourage the innovation and development of preparations. National Medical Products Administration has successively issued relevant registration and approval policy documents to promote the implementation of various policies related with innovative preparations. With low R&D investment，short cycle，low risk，and broad market prospects，innovative preparations become an important product development direction for pharmaceutical companies under the “4+7” volume-based procurement policy for generic drugs. As an important technical platform for the development of innovative preparations，solid preparations can achieve long-term effect，sustained and controlled release，intestinal targeting，multiple drug deliveries and other functions through advanced technical means，which solve the limitations of drugs in clinical use，and achieve the clinical goals of better efficacy，fewer side effects and better patient compliance to meet the needs of both doctors and patients.